ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update

4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320...

Related Keywords

Florida ,United States ,Boca Raton ,Adam Grossman ,Michelle Pappanastos ,Nasdaq ,Business Development ,Drug Administration ,Exchange Commission ,Biologics Inc ,Unaudited Total Revenue ,Revenue Guidance Increased ,Income Expected ,Opportunities Targeting Manufacturing ,New Pipeline Hyperimmune Globulin ,Advance During ,Chief Executive Officer ,Growth Opportunities ,Production Yield Enhancement ,Pipeline Introduction ,Hyperimmune Globulin ,United States Food ,Adverse Reactions ,Private Securities Litigation Reform Act ,Corporate Strategy ,Managing Director ,Argot Partners ,Markets ,